Top

Published in:

01-02-2014 | Research Article

Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice

Authors: Linda E. B Stuhr, Eddie T. Wei, Rolf K. Reed

Published in: Tumor Biology | Issue 2/2014

Abstract

The present study examines the effect of the endogenous neuroendoccrine factor, corticotropin-releasing factor (CRF), alone or in combination with 5-fluorouracil (5-FU), on 4T1 mammary tumor cells in vitro and in vivo. CRF has been detected in breast cancer tissues; however, the biological effects reported in the literature are sparse and variable. We found that exogenously administered CRF significantly reduced tumor growth without influencing angiogenesis or cell death. Furthermore, CRF reduced tumor interstitial fluid pressure (P_if) and potentiated the effect of 5-FU. These results show that CRF has antitumor effect on mammary carcinoma in mice.

Androulidaki A, Dermitzaki E, Venihaki M, Karagianni E, Rassouli O, Andreakou E, et al. Corticotropin releasing factor promotes breast cancer cell motility and invasiveness. Mol Cancer. 2009;8:30.PubMedCentralPubMedCrossRef

Arranz A, Venihaki M, Mol B, Androulidaki A, Dermitzaki E, Rassouli O, et al. The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress. Mol Cancer. 2010;9:261.PubMedCentralPubMedCrossRef

Beaumont A, Marmarou A. The effect of human corticotrophin releasing factor on the formation of post-traumatic cerebral edema. Acta Neurochir Supplement. 1998;71:149–52.

Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Ann Re Chem Biomol Eng. 2011;2:281–98.CrossRef

Ciocca DR, Puy LA, Fasoli LC, Tello O, Aznar JC, Gago FE, et al. Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat. 1990;15:175–84.PubMedCrossRef

Friman T, Gustafsson R, Stuhr LB, Chidiac J, Heldin NE, Reed RK, et al. Increased fibrosis and interstitial fluid pressure in two different types of syngeneic murine carcinoma grown in integrin beta3-subunit deficient mice. PloS One. 2012;7:e34082.PubMedCentralPubMedCrossRef

Gjerde EA, Woie K, Wei ET, Reed RK. Corticotropin-releasing hormone inhibits lowering of interstitial pressure in rat trachea after neurogenic inflammation. Eur J Pharmacol. 1998;352:99–102.PubMedCrossRef

Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, et al. Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol. 2007;264:44–9.PubMedCrossRef

Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806–13.PubMedCrossRef

10.

Hofmann M, McCormack E, Mujic M, Rossberg M, Bernd A, Bereiter-Hahn J, et al. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model. Neoplasia. 2009;11:812–22.PubMedCentralPubMed

11.

Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47:3039–51.PubMed

12.

Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9:253–66.PubMedCrossRef

13.

Kaprara A, Pazaitou-Panayiotou K, Chemonidou MC, Constantinidis TC, Lambropoulou M, Koffa M, et al. Distinct distribution of corticotropin releasing factor receptors in human breast cancer. Neuropeptides. 2010;44:355–61.PubMedCrossRef

14.

Kim BJ, Jones HP. Implications of corticotropin releasing factor in targeted anticancer therapy. J Pharm Pract. 2010;23:86–90.PubMedCrossRef

15.

Klosowska-Wardega A, Hasumi Y, Burmakin M, Ahgren A, Stuhr L, Moen I, et al. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma. PloS One. 2009;4:e8149.PubMedCentralPubMedCrossRef

16.

Oldberg A, Kalamajski S, Salnikov AV, Stuhr L, Morgelin M, Reed RK, et al. Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci U S A. 2007;104:13966–71.PubMedCentralPubMedCrossRef

17.

Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev. 1991;43:425–73.PubMed

18.

Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62:5476–84.PubMed

19.

Radulovic M, Hippel C, Spiess J. Corticotropin-releasing factor (CRF) rapidly suppresses apoptosis by acting upstream of the activation of caspases. J Neurochem. 2003;84:1074–85.PubMedCrossRef

20.

Reed RK, Rubin K. Transcapillary exchange: role and importance of the interstitial fluid pressure and the extracellular matrix. Cardiovasc Res. 2010;87:211–7.PubMedCrossRef

21.

Rodt SA, Reed RK, Ljungstrom M, Gustafsson TO, Rubin K. The anti-inflammatory agent alpha-trinositol exerts its edema-preventing effects through modulation of beta 1 integrin function. Circ Res. 1994;75:942–8.PubMedCrossRef

22.

Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J: Off Publication Fed Am Soc Exp Biol. 2003;17:1756–8.

23.

Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin NE, Rubin K. Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest. 2005;85:512–21.PubMedCrossRef

24.

Slominski A, Zbytek B, Nikolakis G, Manna PR, Skobowiat C, Zmijewski M, et al. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol. 2013. doi:10.1016/j.jsbmb.2013.02.006.

25.

Stuhr LE, Moen I, Nedrebo T, Salnikov AV, Wiig H, Rubin K, et al. Peritumoral TNFalpha administration influences tumour stroma structure and physiology independently of growth in DMBA-induced mammary tumours. Scand J Clin Lab Invest. 2008;68:602–11.PubMedCrossRef

26.

Tjuvajev J, Kolesnikov Y, Joshi R, Sherinski J, Koutcher L, Zhou Y, et al. Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In vivo. 1998;12:1–10.PubMed

27.

Wei ET, Gao GC. Corticotropin-releasing factor: an inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury. Regul Pept. 1991;33:93–104.PubMedCrossRef

28.

Wei ET, Thomas HA. Anti-inflammatory peptide agonists. Annu Rev Pharmacol Toxicol. 1993;33:91–108.PubMedCrossRef

29.

Wei ET, Thomas HA, Christian HC, Buckingham JC, Kishimoto T. d-Amino acid-substituted analogs of corticotropin-releasing hormone (CRH) and urocortin with selective agonist activity at CRH1 and CRH2beta receptors. Peptides. 1998;19:1183–90.PubMedCrossRef

Title: Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice
Authors: Linda E. B Stuhr
Eddie T. Wei
Rolf K. Reed
Publication date: 01-02-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1186-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Erratum to: Prognostication of OCT4 isoform expression in prostate cancer

Expression of HAX-1 in human colorectal cancer and its clinical significance

Analysis of the association of interleukin-17 gene polymorphisms with gastric cancer risk and interaction with Helicobacter pylori infection in a Chinese population

Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53

Prognostic factors of carcinoma of the ampulla of Vater after surgery

Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk

Keynote webinar | Spotlight on antibody–drug conjugates in cancer